top of page
Up stories


Abivin logo transparent blue.png
  • Founded in 2015, Abivin provides an AI-powered optimization platform for companies in the APAC region. With proprietary algorithms that can automatically address ingrained logistics mathematical problems, Abivin optimizes the enterprise value chains by helping companies save 10-30% logistics costs, increase 30% delivery capacity, improve the end-to-end supply chain visibility, and reduce carbon footprints.

Abivin won 2019 #StartupWorldCup Grand Finale Champion and has raised over US$1.7million in seed and pre-series A financing from Pegasus Tech Ventures, Access Ventures and others. As a Vietnam-born logitech startup, Abivin is blazing a path in comprehensively integrating four main capabilities: transportation management, intelligence dashboard, 3D loading optimization, and route optimization. 


The key components that set Abivin apart from other competitors are its proprietary optimization algorithms and technical capability in big data analytics, AI, and machine learning, which can assist people in making complex planning decisions automatically while satisfying more than 30 constraints. 


Founded by an M.A. in computer science at the University of Cambridge and a former engineer at Google, Abivin has successfully expanded across six countries, including Vietnam, Indonesia, Myanmar, Singapore, the Philippines, and Japan. The company has an impressive client portfolio with the top 10 biggest corporations in Vietnam and in the world, achieving the CAGR of annual recurring revenue at 3x over the 2016-2021 period. 


Many companies are running logistics operations manually without the support of advanced computing power. This causes long-hour route planning, ineffective on-field work or low-quality customer services and a lack of visibility over the supply chain. 

Since the onslaught of the COVID-19 pandemic, these problems have hit the logistics sector hard and exposed how much companies can make or break their future successes. 


“If an optimal data-driven route is available and drivers, salesmen, warehousemen are enabled to update working progress, communicate, and receive supervisors’ tasks, logistics services could gain more capabilities, save up working time and operating costs,” said Pham Nam Long, Abivin’s CEO and founder. “Our vision is to cut the logistics cost of Southeast Asian countries down to below 10% of their GDPs, putting them on par with those of North America and Europe’s countries.”


Abivin recently secured the top 4 winning startups of Microsoft’s inaugural Emerge X Competition in the Asia Pacific region in 2020 and became the winner of the ASEAN Entrepreneur Award 2020 hosted by ASEAN-Korea Centre and Maeil Business Newspaper. 



  • Leuko is a startup spun out from MIT and the Madrid M+Vision Consortium. They are developing a platform technology to noninvasively measure blood parameters. The scalable PointCheck™ solution combines optics and AI to make blood testing easier, faster, more accessible, and cost-effective than the state-of-the art solutions. In 2017, Carlos Castro-Gonzalez, Aurelien Bourquard, Ian Butterworth and Alvaro Sanchez-Ferro co-founded Leuko. Together they co-invented Leuko’s proprietary PointCheck™ technology for non-invasive white blood cell monitoring.

Leuko Labs was our 2018 #StartupWorldCup Grand Finale Champion who have announced yesterday that they have raised $1.8 million seed round. Leuko Labs is a MIT-born technology startup developing the first non-invasive white blood cell monitoring device.

They raised $1.8 million in seed financing from Pegasus Tech Ventures, Good Growth Capital, Nina Capital, and others.

Founded by four MIT scientists and entrepreneurs, two of whom are also alumni of Universidad Politécnica de Madrid, Leuko is  developing PointCheck™, the company’s proprietary device to measure white blood cell levels non-invasively, which can enable improved clinical outcomes and reduced costs for immunosuppressed patients. The device takes its measurements from a patient’s finger without drawing blood.


Patients need a way to monitor how they are reacting to treatments, daily and non-invasively from the comfort of their homes, and physicians need this insight to more precisely adjust treatments. If physicians are alerted when a patient's white blood cells drop to dangerously-low levels, preventive treatment could be deployed to avoid life-threatening infections, improve clinical outcomes, and reduce hospitalization costs. “Our vision is that patients will have a PointCheck™ portable device that they can take home to do just that,” said Carlos Castro-Gonzalez, Leuko’s CEO and co-founder. "The new investment supports ongoing development and clinical studies of our platform technology, to ultimately turn this vision into reality.”

Good Growth Capital (GGC), a venture capital fund based between Boston and Charleston and focused on early stage technology companies, has led the investment.

“In the short time since GGC’s first investment, Leuko has made significant progress in developing a platform that is demonstrably faster, more efficient and more scalable than traditional methods,” said Amy Salzhauer, managing partner at GGC. “We’re excited to invest in Leuko and help accelerate their path to market as they aim to transform the care of immunosuppressed patients by dramatically improving the efficiency of cell testing.”



  • Founded in 2013 in Japan, UniFa develops an IoT solution for tracking kindergarteners' physical and mental growth
  • Launched new service "Look-me nap check," which offers a simple button from the sensor to support safety and security of children by monitoring children's sleep
  • $10M funding after they became the Startup World Cup 2017 champion
  • 8 famous Japanese venture funds and corporations
  • 6x increase in sales

  • 3x increase in customer 

  • 2x increase in employees

  • Partnership with Toppan Printing, Froebel-Kan, and more

  • Expected IPO in 2020 

*Disclaimer: The above information is presented for illustrative purposes only. UniFA is not a portfolio holding of SWC Fund. This presentation is not intended as a recommendation to purchase or sell any security.  Past performance of these strategies is not necessarily indicative of future results. Pegasus Tech Ventures makes no implications, warranties, promises, suggestions or guarantees whatsoever, in whole or in part, that by participating in any investment of or with Pegasus Tech Ventures you will experience similar investment results. There is the possibility of loss and all investment involves risks including the loss of principal.  This presentation was prepared by Pegasus Tech Ventures and is believed by the Pegasus Tech Ventures to be reliable and has been obtained from public sources believed to be reliable. Pegasus Tech Ventures makes no representation as to the accuracy or completeness of such information. 

bottom of page